Lynch Receives Bristol-Myers Squibb Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

NEW YORK--Henry T. Lynch, MD, whose pioneering work during the 1960s and '70s helped establish the hereditary basis of certain gastrointestinal, breast, and ovarian cancers, is the recipient of the 19th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research. Thanks in large part to Dr. Lynch, the specific genetic mutations responsible for a number of familial cancers have been identified.

NEW YORK--Henry T. Lynch, MD, whose pioneering work during the1960s and '70s helped establish the hereditary basis of certaingastrointestinal, breast, and ovarian cancers, is the recipientof the 19th annual Bristol-Myers Squibb Award for DistinguishedAchievement in Cancer Research. Thanks in large part to Dr. Lynch,the specific genetic mutations responsible for a number of familialcancers have been identified.

Dr. Lynch is professor of medicine and chairman of preventivemedicine and public health, Creighton University School of Medicine,Omaha.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content